protionamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2314	14222-60-7

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

prothionamide
2-Propylisonicotinylthioamide
2-Propylthioisonicotinamide
protionamid
protionamide

Antitubercular agent similar in action and side effects to ETHIONAMIDE. It is used mostly in combination with other agents.

Molecular weight: 180.27
Formula: C9H12N2S
CLOGP: 2.26
LIPINSKI: 0
HAC: 2
HDO: 1
TPSA: 38.91
ALOGS: -2.79
ROTB: 3

Drug dosage:

Dose	Unit	Route
0.75	g	O

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Electrocardiogram QT prolonged	81.68	43.86	24	305	59506	63429187
Hepatotoxicity	78.46	43.86	21	308	37020	63451673
Drug resistance	48.41	43.86	13	316	22920	63465773

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatotoxicity	240.84	53.00	60	623	21425	34934823
Electrocardiogram QT prolonged	122.41	53.00	41	642	40911	34915337

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatotoxicity	306.22	44.71	81	1024	51271	79692012
Electrocardiogram QT prolonged	190.83	44.71	64	1041	90322	79652961
Drug resistance	58.59	44.71	22	1083	42191	79701092

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J04AD01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Thiocarbamide derivatives
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000995	Antitubercular Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.43	acidic
pKa2	5.65	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Polyphenol oxidase 2	Enzyme		PPO2_AGABI		IC50	5.35		CHEMBL

External reference:

ID	Source
N0000167317	NUI
D01195	KEGG_DRUG
C0033705	UMLSCUI
CHEBI:32066	CHEBI
CHEMBL1378024	ChEMBL_ID
DB12667	DRUGBANK_ID
2031	INN_ID
76YOO33643	UNII
666418	PUBCHEM_CID
8871	RXNORM
006706	NDDF
703589003	SNOMEDCT_US
714517006	SNOMEDCT_US
D011515	MESH_DESCRIPTOR_UI

Pharmaceutical products:

None